阿普米司特(Apremilast) - 药物靶点：PDE4_在研适应症：手掌和足底脓疱病，白塞病/贝赫切特综合征，口腔溃疡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Apremilast (JAN/USAN)、pms-APREMILAST、阿普斯特

+ [7]

靶点

PDE4

作用方式

抑制剂

作用机制

PDE4抑制剂(磷酸二酯酶4抑制剂)

治疗领域

免疫系统疾病感染心血管疾病+ [6]

在研适应症

手掌和足底脓疱病白塞病/贝赫切特综合征口腔溃疡+ [10]

非在研适应症

聚合性痤疮酗酒强直性脊柱炎+ [22]

原研机构

Celgene Corp.

在研机构

Amgen, Inc.Amgen Europe BVAccord Healthcare SLU

+ [5]

非在研机构

上海复星医药（集团）股份有限公司

The Scripps Research Institute

权益机构

Quantumleap Healthcare Collaborative

Amgen, Inc.

上海复星医药（集团）股份有限公司

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2014-03-21),

银屑病关节炎

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

分子式C22H24N2O7S

InChIKeyIMOZEMNVLZVGJZ-QGZVFWFLSA-N

CAS号608141-41-9

关联

208

项与阿普米司特相关的临床试验

NCT07398651

/ Not yet recruitingN/AIIT

Comparative Study Between Apremilast and Adalimumab in Psoriatic Arthritis Patients

The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate

开始日期2026-12-30

申办/合作机构

Tanta University

NCT07366268

/ Not yet recruitingN/AIIT

Evaluation of Topical Apremilast Nanoparticles in the Treatment of Plaque Psoriasis: Clinical, Histopathological and Immunohistochemical Study

This study is a comparative randomized clinical trial evaluating the efficacy and safety of topical apremilast nanoemulsion 0.3% in the treatment of localized mild to moderate plaque psoriasis.Clinical efficacy will be assessed using TES score, Physician Global Assessment (PGA), dermoscopy, and patient satisfaction, while safety is monitored through adverse effect reporting. In addition, histopathological and immunohistochemical evaluation of PDE4 expression will be performed before and after treatment to assess tissue-level responses.
The study aims to determine whether topical apremilast nano-formulation, alone or combined with corticosteroids, offers an effective and safer alternative to conventional topical therapy, with improved local efficacy and reduced corticosteroid-related adverse effects.

开始日期2026-05-01

申办/合作机构

Assiut University

NCT07325266

/ Not yet recruiting临床2期IIT

Human Laboratory Study of Apremilast for Alcohol Use Disorder

Primary: The primary objective of this study is to compare the efficacy of two different maintenance doses of apremilast (tablets) in reducing alcohol craving among subjects with moderate to severe alcohol use disorder (AUD) after two weeks of daily dosing.
Secondary: Secondary objectives include evaluation of two different maintenance doses of apremilast compared with matched placebo on other measures of self-reported alcohol consumption, alcohol craving, alcohol-related negative consequences, AUD symptoms, pain, sleep disturbances, depression, anxiety, quality of life, cigarette smoking, other nicotine use, cannabis use, retention in the study, and safety.

开始日期2026-04-01

申办/合作机构

National Institute on Alcohol Abuse & Alcoholism

100 项与阿普米司特相关的临床结果

登录后查看更多信息

100 项与阿普米司特相关的转化医学

登录后查看更多信息

100 项与阿普米司特相关的专利（医药）

登录后查看更多信息

1,429

项与阿普米司特相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Article

作者: Zhdanava, Maryia ; Fitzgerald, Timothy ; Feldman, Steven R. ; Boonmak, Porpong ; Schwartzbein, Samuel ; Libchaber, Béatrice ; Pilon, Dominic

OBJECTIVE:

To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.

MATERIALS AND METHODS:

This retrospective cohort study used U.S. claims data from the IQVIA PharMetrics® Plus database (2016- 2023). Overlap propensity score weights were used to balance cohorts on baseline characteristics. On-label persistence was defined as the absence of drug discontinuation (event) and any dose change relative to the U.S. label (censoring). Survival analyses were used to assess on-label persistence from the start of the maintenance phase.

RESULTS:

At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001).

CONCLUSIONS:

Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.

2026-06-01·Bone Reports

Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential

Review

作者: Ursachi, Vlad-Constantin ; Fafilek, Bohumil ; Horak, Jan

Skeletal disorders such as osteoporosis, osteoarthritis, and rheumatoid arthritis represent major global health burdens with limited therapeutic innovation. Inhibitors of phosphodiesterases (PDEs), enzymes that regulate the intracellular levels of the cyclic nucleotides cAMP and cGMP, are increasingly recognized as potential medications that can improve the health of bone and cartilage. Although they have been used in clinics for decades, their function in bone or cartilage remains unclear. In preclinical models, inhibitors that target PDE3 (e.g., cilostazol, milrinone), PDE4 (roflumilast, apremilast), and PDE5 (e.g., sildenafil, avanafil, vardenafil) exhibit promising anabolic, anticatabolic, and anti-inflammatory effects on skeletal tissues. Broad-spectrum inhibitors such as pentoxifylline and dipyridamole also demonstrate dual benefits in terms of bone regeneration and joint preservation. This review examines the mechanistic basis and therapeutic potential of clinically approved PDE inhibitors-originally developed for cardiovascular, neurological, and inflammatory conditions-for skeletal applications. Understanding the mechanism of action of PDE inhibitors can facilitate their translation into the clinic, help with their application in combined therapies, or minimize their potential adverse effects. This approach offers a cost-effective and viable path toward novel therapies for musculoskeletal health.

2026-03-01·JOURNAL OF DERMATOLOGY

Apremilast Associated Clinical Improvement in Bullous Pemphigoid With Plaque Psoriasis

Letter

作者: Takemoto, Keita ; Kitayama, Shohei ; Shirasaki, Fumiaki ; Shimizu, Tadamichi ; Mizawa, Megumi ; Makino, Teruhiko

1,045

项与阿普米司特相关的新闻（医药）

2026-04-02

·EndPoints

Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 miss

Alto Neuroscience said its PDE4 inhibitor failed a mid-stage trial in schizophrenia-related cognitive impairment, prompting the biotech to drop plans to advance the program on its own. Alto said Wednesday it no longer intends to “independently” develop the asset, called ALTO-101, for cognitive impairment associated with schizophrenia (CIAS). The company will instead focus its resources on its lead candidate, called ALTO-207. That program is set to enter a Phase 2b trial for treatment-resistant depression in the first half of the year. Alto said it will also search for a partner to help advance a modified-release pill version of ALTO-101 it has developed. This is a different formulation from the one that flunked the CIAS study, which was a transdermal patch. The company’s shares $ANRO were down by as much as 13% premarket Thursday. Alto’s placebo-controlled Phase 2 study was designed to test the patch version of ALTO-101 in 82 patients with schizophrenia and cognitive impairment. The drug was not statistically significantly better than placebo on the trial’s key endpoints, which looked at improvements in cognitive function and changes on a brain activity test known as electroencephalography (EEG). The one silver lining of Wednesday’s miss was that the frequency of nausea and vomiting associated with treatment was similar to placebo. These side effects are usually a significant problem for PDE4 inhibitors, a class that includes AstraZeneca’s chronic obstructive pulmonary disease drug Daliresp and Amgen’s plaque psoriasis treatment Otezla. Wall Street seemed largely unfazed by the trial miss. In a Wednesday note, William Blair analysts wrote “we had always viewed the study as high risk given the signal-finding nature, short-term study, and difficult-to-treat CIAS population.” Stifel analysts wrote the day of the data release that “investor focus continues to remain on ALTO-207.” CIAS is a notoriously challenging area with a history of trial failures. In July 2025, Recognify Life Sciences’ candidate flunked a Phase 2b study . Earlier that year, Boehringer Ingelheim’s GlyT1 inhibitor iclepertin failed a Phase 3 trial . A different GlyT1 inhibitor developed by Pfizer was also unable to improve CIAS symptoms in a Phase 2 trial.

临床2期临床3期

2026-04-02

·银友新药交流群

银屑病新药这么多，怎么选？我来给你说清楚

随着新型药物和精准治疗策略的不断涌现，在银屑病治疗方式转型过程中所遇到的停药复发、治疗间隔、药物选择等方面问题，都给银屑病治疗策略的优化带来了思辨。在AAD2025年度会议上，来自耶鲁大学医学院的Bruce Strober教授为大家带来了银屑病治疗领域的最新热点。 1、早期强效治疗策略：获得持久疗效银屑病患者通常需要终身治疗，既往生物制剂治疗往往用于传统治疗无效的患者中，接受生物制剂治疗前平均病程约为20年。GUIDE研究中评估了长（LDD）、短病程（SDD）患者在古塞奇尤单抗（Guselkumab）常规治疗28周后以间隔8周或16周的频率进行维持给药，第68周达到绝对PASI<3的比例。结果表明SDD患者达到稳定皮损清除的可能性更高。值得注意的是，与LDD患者相比，SDD的PASI90及以上反应率更高且实现速度明显更快，提示应用Guselkumab进行早期疾病干预为患者提供了更大的益处。这可能与IL-23可显著降低组织驻留记忆T细胞（tissue-resident memory, TRM）功能有关[1]。图1. Guselkumab停药后超级应答者的维持阶段. Presented by Bruce Strober in AAD, 2025 2、优化单克隆抗体：降低给药频率 Fc段是抗体类药物的核心功能区域，Fc与FcRn结合可以有效避免被溶酶体降解，并再次释放到血液中，是延长抗体药物半衰期的关键机制之一。YTE突变是指对Fc段中三个关键氨基酸（M252Y/S254T/T256E）进行替换，通过引入带负电荷的谷氨酸（T256E）和极性残基来优化Fc段与FcRn的静电互补性，显著提高血液中酸性条件下的结合效率，避免被溶酶体降解，增强药物半衰期，减少给药频率。目前研究者们设计制备了一种针对银屑病治疗的长效药物ORKA-001，这一靶向IL-23p19的新型单克隆抗体不仅对Fc段进行了YTE修饰，同时构建了人源化的Fc段，进一步提高了Fc与FcRn的结合效率，并能有效减少免疫原性。与同为靶向IL-23p19的利生奇珠单抗（risankizumab）相比，ORKA-001抑制IL-17释放效力与其相当，但半衰期延长30倍以上且稳态浓度显著优于risankizumab。图2. 单克隆抗体ORKA-001结构示意图及药物效能Presented by Bruce Strober in AAD, 2025 3、口服药物革新：肽类IL-23受体拮抗剂与高选择性TYK2抑制剂治疗银屑病需新的、有效且耐受性良好的口服疗法以适应不同人群需要。（1）肽类IL-23受体拮抗剂目前，尚缺乏有效针对银屑病的口服靶向药物。JNJ-77242113（Icotrokinra）作为一种化学合成的大环肽，以高亲和力与人IL-23R细胞外结构域（ECD）结合，并以浓度依赖性方式抑制IL-23诱导的STAT3磷酸化。这是第一个可以口服递送的选择性IL-23通路调节剂。在最近对中度至重度银屑病患者进行的一项2期研究中（FRONTIER-1），研究者们评估了Icotrokinra在中重度斑块型银屑病患者中的疗效和安全性。通过16周用药观察，Icotroknra组患者的PASI 75应答率高于安慰剂组，且呈现显著的剂量-效应关系。各组不良事件发生率总体相似，且未随药物剂量增加而升高。在FRONTIER-2研究中延长了随访观察时间至52周，结果显示100mg/每日2次的给药方式患者获益最高，76%的患者达到PASI 75。进一步的3期研究结果表明16周PASI 90应答率即可达50%，安全性良好[2-3]。图3. Icotrokinra在二/三期药物研究中疗效表现优异Presented by Bruce Strober in AAD, 2025 （2）高选择性变构酪氨酸激酶2（TYK2）抑制剂 TYK2是一种Janus激酶（JAK）相关介质，是治疗银屑病新型口服药物的一个潜在靶点，通过JAK信号转导和转录途径激活剂参与细胞内信号转导。Zasocitinib是除外氘可来昔替尼片（Deucravacitinib）的另一种高选择性口服TYK2变构抑制剂。与Deucravacitinib不同的是，Zasocitinib对TYK2的JH2结构域表现出更高的选择性。仅治疗12周，就有多达三分之一的患者实现皮肤症状完全清除，且已知耐受性问题发生率较低，未出现JAK1-3抑制剂特有的严重毒性反应[4]。图4.Zasocitinib二期临床有效性数据 Presented by Bruce Strober in AAD, 2025 同时，Bruce教授也指出，“高影响、低BSA”类型的银屑病值得引起大家关注，是未来一段时间临床试验的新焦点。来自耶鲁大学医学院皮肤科的Mona Shahriari和Jeffrey Cohen教授也对这类难治性银屑病的治疗方式进行了解读，并结合近期高质量临床研究数据，分析了银屑病真实世界的方案选择，为口服药物和生物制剂在临床上的应用取舍提供了方向。自2004年开始，随着银屑病系统治疗药物的大规模研发与应用，医患的用选择也变得丰富起来。通常治疗方案的考量因素主要包括：皮损短期/常期疗效、安全性、成本、特殊部位受累、关节疗效、合并症、既往治疗反应、患者偏好等。 1、“头对头”临床研究：疗效金标准（1）依奇珠单抗（Ixekizumab）vs.阿达木单抗（Adalimumab）（SPIRIT-H2H）：Ixekizumab在改善皮肤和关节症状方面更优；两者ACR 50应答率相当。（2）Ixekizumabvs. Guselkumab（IXORA-R）：Ixekizumab在12周能更快实现皮损的完全清除，24周效果相当。（3）比美吉珠单抗（Bimekizumab）vs.司库奇尤单抗（Secukinumab）（BE RADIANT）：Bimekizumab第16周PASI 100应答率更高。 2、“高影响、低BSA”：关注特殊部位的难治性银屑病特殊部位银屑病BSA低但常面临局部治疗失败的问题，国际共识推荐使用系统药物进行干预。（1）头皮银屑病：推荐治疗阶梯依次为：IL-17抑制剂、IL-23抑制剂、JAK抑制剂。但需注意的是，仅古塞奇尤单抗（GUS），司库奇尤单抗（SEC）和阿普米斯特（apremilast）在FDA说明中纳入了治疗头皮银屑病的有效性数据。（2）角化型掌跖脓疱型银屑病：推荐治疗阶梯依次为：JAK抑制剂、IL-23或IL-17抑制剂、甲氨蝶呤、Deucravacitinib、生物制剂联合口服系统药物。（3）反向型银屑病：系统治疗推荐IL-23、IL-17抑制剂、Apremilast、Deucravacitinib[5]；局部治疗推荐维生素D衍生物、钙调磷酸酯酶抑制剂、Roflumilast乳膏、Tapinarof乳膏，糖皮质激素慎用。可联合局部窄波紫外线。（4）甲银屑病：局部治疗可使用维生素D衍生物、钙调磷酸酯酶抑制剂、维A酸、水杨酸，必要时可联用。也可在甲周行激素局部注射治疗。传统系统疗法中推荐使用甲氨蝶呤、阿维A；免疫调节治疗推荐生物制剂、JAK抑制剂及TYK2抑制剂。Ixekizumab、Bimekizumab在“头对头”研究中显示出不错的疗效；Risankizumab在长期维持治疗中显示出优越的稳定性。口服药物中，Deucravacitinib与乌帕替尼缓释片（Upadacitinib）对甲银屑病的清除效率约为50%[6]。（5）泛发性脓疱型银屑病（GPP）：佩索利单抗（Spesolimab）是目前FDA唯一批准针对GPP的靶向IL-36R单抗，可有效治疗并减少复发。但需注意，GPP患者中70%合并其他系统疾病，需要关注长期管理。图5. Apremilast对反向型银屑病的治疗效果Presented by Jeffrey Cohen in AAD, 2025 图6. Risankizumab显示出对甲银屑病的持续缓解Presented by Jeffrey Cohen in AAD, 2025 银屑病治疗领域在新型药物和治疗策略的推动下，正迎来前所未有的发展机遇。未来，随着更多“头对头”临床研究的推进，以及新型靶点药物的深入探索，银屑病治疗将更加个体化、精准化。同时，真实世界数据的积累与跨学科协作的深化，有望进一步优化治疗决策为患者带来更高质量的生存获益。扫码报名临床，免费用新药，当地三甲医院用药扫码进银屑病/银屑病关节炎病友交流群

2026-04-02

·drugs

New Pill Could Change Plaque Psoriasis Treatment

THURSDAY, April 2, 2026 — Folks with severe plaque psoriasis often have to choose between convenient pills that don’t work very well or highly effective injections that come with the hassle of needles. That trade-off may soon change. New clinical trial data suggests a once-daily pill called zasocitinib may provide the clear skin once only expected from shots. The medicine is in the final stages of study and is not yet approved by the U.S. Food and Drug Administration (FDA). Takeda Pharmaceuticals recently shared results from two late-stage clinical trials involving nearly 1,800 adults with moderate-to-severe plaque psoriasis across 21 countries. The findings — presented at a meeting of the American Academy of Dermatology in Denver last month — showed that about 70% of participants taking the pill reached the goal of having clear or almost clear skin within 16 weeks. Plaque psoriasis makes skin cells grow too fast, forming thick, scaly raised red patches with silvery scales. It causes itching and burning feelings on the skin during flare-ups. The studies compared zasocitinib to a placebo and to apremilast , a widely available pill for psoriasis. About 30% of patients on apremilast saw significant skin improvement, compared to more than double that amount with zasocitinib. Researchers reported that zasocitinib worked with surprising speed. Many patients noticed their skin starting to clear as early as four weeks into the treatment. The results were lasting: Of the patients who had clear skin at the nine-month mark, more than 90% still maintained those results after more than a year of daily use. “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said lead researcher Dr. Melinda Gooderham , a dermatologist in Ontario, Canada. She added that these results show it is possible for a daily pill to deliver rapid, lasting relief. No new or unexpected safety concerns were discovered during the trials. The most common side effects reported were generally mild, such as upper respiratory infections like a common cold. About 6.5% of patients taking the drug also experienced acne, which is a known side effect of this specific class of medication, called TYK2 inhibitors. “Our Phase 3 results demonstrate that highly selective TYK2 inhibition can offer many people with moderate-to-severe plaque psoriasis the potential for clear or nearly clear skin,” said Dr. Chinweike Ukomadu , a senior vice president at Takeda and head of the company’s gastrointestinal and inflammation areas. Takeda plans to submit the drug to the FDA for approval within the next year. Findings from medical conferences are considered preliminary until published in a peer-reviewed journal. Sources Takeda Pharmaceutical Company Limited, news release, March 28, 2026

临床结果临床3期

100 项与阿普米司特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08860	阿普米司特	L04AA32	DB05676

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
手掌和足底脓疱病	日本	Amgen KK	2025-03-27
白塞病/贝赫切特综合征	美国	Amgen, Inc.	2019-07-19
口腔溃疡	澳大利亚	Amgen Australia Pty Ltd.	2015-03-19
斑块状银屑病	欧盟	Amgen Europe BV	2015-01-15
斑块状银屑病	冰岛	Amgen Europe BV	2015-01-15
斑块状银屑病	列支敦士登	Amgen Europe BV	2015-01-15
斑块状银屑病	挪威	Amgen Europe BV	2015-01-15
银屑病	美国	Celgene Corp.	2014-09-23
银屑病关节炎	美国	Amgen, Inc.	2014-03-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
自身免疫性疾病	申请上市	中国	三生制药公司	2022-01-30
脓疱型银屑病	临床3期	日本	Amgen, Inc.	2022-03-08
生殖器疾病	临床3期	美国	Amgen, Inc.	2022-01-30
幼年特发性关节炎	临床3期	美国	Amgen, Inc.	2022-01-30
新型冠状病毒感染	临床3期	美国	Amgen, Inc.	2020-11-24
新型冠状病毒感染	临床3期	阿根廷	Amgen, Inc.	2020-11-24
新型冠状病毒感染	临床3期	巴西	Amgen, Inc.	2020-11-24
新型冠状病毒感染	临床3期	智利	Amgen, Inc.	2020-11-24
新型冠状病毒感染	临床3期	墨西哥	Amgen, Inc.	2020-11-24
新型冠状病毒感染	临床3期	俄罗斯	Amgen, Inc.	2020-11-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06509984 (EBULO, Pubmed \| BMJ Open)	临床2期	单纯性大疱性表皮松解症	14	Apremilast	積夢鏇蓋選範糧構窪衊(齋觸遞淵選顧鏇廠壓範) = 齋獵淵鬱艱鏇簾構網淵夢鏇製夢膚選夢遞築餘 (遞鏇鹽餘憲顧壓醖簾範 )	积极	2025-11-01
NCT03747939 (FOREMOST, ACR2025)	临床3期	银屑病关节炎	308	Apremilast	願夢艱觸餘築鏇夢壓觸(襯鹽築醖鏇簾築襯糧簾) = 糧鹹鬱糧淵糧齋糧簾鹽願觸蓋襯窪製獵製糧網 (繭衊製選範壓憲廠餘顧 ) 更多	积极	2025-10-24
				Placebo	願夢艱觸餘築鏇夢壓觸(襯鹽築醖鏇簾築襯糧簾) = 製艱餘積齋獵構製網憲願觸蓋襯窪製獵製糧網 (繭衊製選範壓憲廠餘顧 ) 更多
NCT03747939 (FOREMOST, ACR2025)	临床3期	银屑病关节炎	308	Apremilast (APR)	淵願糧積觸窪鏇觸膚鬱(餘構壓鹹淵衊範鬱齋窪): OR = 0.42 (95.0% CI, 0.22 ~ 0.77)	积极	2025-10-24
				Placebo (PBO)
NCT03783026 (MOSAIC, ACR2025)	临床4期	-	32	Apremilast 30 mg (Baseline dactylitis)	齋衊艱艱積膚積簾積淵(衊繭窪壓夢蓋鏇壓鏇築) = Statistically significant decreases in DEMRIQ-Vol (W24 and W48) and DEMRIQ-ME (W48) were observed for the MRI-determined most-affected joint (P< 0.05); DEMRIQ-IRE showed no significant change. 鬱膚繭膚顧鏇憲憲醖憲 (衊憲艱選範鹽衊鏇醖窪 ) 更多	积极	2025-10-24
NCT03747939 (FOREMOST, ACR2025)	临床4期	银屑病关节炎	308	Apremilast	鑰構鑰遞構艱壓遞鏇遞(遞願襯選網觸鑰窪鹹壓) = 衊淵遞襯鬱窪積艱鹽築網鏇襯鑰餘鑰襯壓願夢 (構膚遞選顧窪廠廠廠網 ) 更多	积极	2025-10-24
				Placebo	鑰構鑰遞構艱壓遞鏇遞(遞願襯選網觸鑰窪鹹壓) = 顧積製構壓構糧網膚壓網鏇襯鑰餘鑰襯壓願夢 (構膚遞選顧窪廠廠廠網 ) 更多
NCT02307513 (BCT-002, FDA_CDER) 人工标引	临床3期	白塞病/贝赫切特综合征	207	Placebo	衊餘範觸齋壓蓋簾網廠(鏇築獵構鬱壓繭壓憲鹽) = 餘遞鏇積衊糧膚蓋齋襯艱襯艱壓餘糧鑰遞願顧 (糧廠遞鑰願網膚醖夢網 ) 更多	积极	2025-08-29
				OTEZLA 30 mg twice daily	衊餘範觸齋壓蓋簾網廠(鏇築獵構鬱壓繭壓憲鹽) = 顧鹽淵觸鏇齋壓顧選糧艱襯艱壓餘糧鑰遞願顧 (糧廠遞鑰願網膚醖夢網 ) 更多
NCT03701763 (PSOR-6, FDA_CDER) 人工标引	临床3期	斑块状银屑病	245	Placebo	鏇獵齋鹹餘簾鹹廠艱遞(繭顧獵窪鑰夢蓋襯觸觸) = 選鑰淵遞顧窪襯觸網窪積觸憲膚構積窪鏇蓋膚 (膚範築憲築遞醖廠鑰願 ) 更多	积极	2025-08-29
				OTEZLA	鏇獵齋鹹餘簾鹹廠艱遞(繭顧獵窪鑰夢蓋襯觸觸) = 製範顧構積積觸餘鹽繭積觸憲膚構積窪鏇蓋膚 (膚範築憲築遞醖廠鑰願 ) 更多
NCT01172938 \| NCT01212757 \| NCT01212770 (FDA_CDER) 人工标引	临床3期	银屑病关节炎	-	Placebo±DMARDs (PsA-1)	鏇鹽鑰齋襯簾鏇鏇鑰範(衊願獵淵鑰遞繭蓋繭襯) = 顧夢廠顧憲網鹹鬱夢鑰構艱廠構選簾鏇觸蓋憲 (襯鏇鹽醖鬱鏇餘鹽餘積 ) 达到更多	积极	2025-08-29
				OTEZLA 30 mg twice daily±DMARDs (PsA-1)	鏇鹽鑰齋襯簾鏇鏇鑰範(衊願獵淵鑰遞繭蓋繭襯) = 獵觸觸鹹築顧膚衊憲鏇構艱廠構選簾鏇觸蓋憲 (襯鏇鹽醖鬱鏇餘鹽餘積 ) 达到更多
NCT03701763 (SPROUT, Pubmed \| Br J Dermatol)	临床3期	斑块状银屑病	245	Apremilast	範襯襯選夢壓簾艱糧壓(範積襯齋窪衊衊襯鹹鏇) = 鹹廠壓範獵齋餘顧構簾鏇積顧觸壓醖廠製製齋 (鑰蓋網廠遞夢遞艱襯簾 ) 更多	积极	2025-07-30
				Placebo	範襯襯選夢壓簾艱糧壓(範積襯齋窪衊衊襯鹹鏇) = 繭壓壓積範餘鹹壓齋簾鏇積顧觸壓醖廠製製齋 (鑰蓋網廠遞夢遞艱襯簾 ) 更多
NCT03747939 (FOREMOST, EULAR2025)	临床3期	银屑病关节炎	308	Apremilast (APR)	製觸膚醖顧積鑰衊網窪(淵蓋淵醖簾範窪蓋憲遞): OR = 0.51 (95.0% CI, 0.27 ~ 0.97) 更多	积极	2025-06-11
				Placebo (PBO)